4//SEC Filing
Xinos Jaime 4
Accession 0000950170-25-113581
CIK 0000949858other
Filed
Sep 7, 8:00 PM ET
Accepted
Sep 8, 4:39 PM ET
Size
12.1 KB
Accession
0000950170-25-113581
Insider Transaction Report
Form 4
Xinos Jaime
Chief Commercial Officer
Transactions
- Exercise/Conversion
Performance Restricted Stock Unit (PRSU)
2025-09-04−20,000→ 80,000 totalExp: 2035-01-28→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2025-09-04+69,000→ 95,286 total - Sale
Common Stock
2025-09-04$2.77/sh−20,854$57,766→ 74,432 total - Exercise/Conversion
Performance Restricted Stock Unit (PRSU)
2025-09-04−49,000→ 0 totalExp: 2028-01-22→ Common Stock (49,000 underlying)
Footnotes (7)
- [F1]Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II.
- [F2]Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement.
- [F5]Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones.
- [F6]Represents PRSUs previously reported on January 30, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors.
- [F7]Pursuant to the terms of the award agreement governing the PRSU, the number of underlying shares of the Issuer's common stock that may ultimately vest ranges from 0% to 100% of the number of the PRSUs initially granted, subject to certain milestones being met during the measurement period.
Documents
Issuer
ACHIEVE LIFE SCIENCES, INC.
CIK 0000949858
Entity typeother
Related Parties
1- filerCIK 0002041627
Filing Metadata
- Form type
- 4
- Filed
- Sep 7, 8:00 PM ET
- Accepted
- Sep 8, 4:39 PM ET
- Size
- 12.1 KB